The company has multiple biosimilar products on the worldwide market and in development; in 2019, it gained World Health Organization precertification for a trastuzumab biosimilar (Ontruzant).
Samsung Bioepis has won the Biosimilar Initiative of the Year award from the publisher Informa and health care analytics company IQVIA. The award is given in recognition of exceptional leadership in expanding access to biosimilars.
In late 2019, Samsung Bioepis, based in Incheon, Republic of Korea, won World Health Organization (WHO) prequalification for its trastuzumab biosimilar Ontruzant. The WHO designation helps to build worldwide acceptance of the agent and expands access to populations in need of lower-cost medicine. Also in 2019, Samsung Bioepis expanded its biosimilar marketing activities in Asia and Latin America.
In August 2020 the company expanded into the Brazilian biosimilars market, considered one of the fastest growing biosimilars markets among emerging nations.
In the United States, the company launched Ontruzant in April 2020 and has 2 biosimilars approved but not yet marketed: Eticovo (etanercept) and Hadlima (adalimumab). Originator product exclusivity rights are keeping these from market. Samsung Bioepis has 5 drug products approved and marketed in Europe in immunology and oncology.
The Biosimilar Initiative award is given to a company with a biosimilar marketed or approved or under development, actively marketing biosimilars, and working to increase biosimilar use and distribution.
“This award is a testament of the tremendous work that we’ve put toward realizing our vision and commitment to become a globally recognized biopharmaceutical company delivering high quality medicines to the people who need them the most,” said Christopher Hansung Ko, president and CEO of Samsung Bioepis.
Informa, based in London, England, and IQVIA, headquartered in Atlanta, Georgia, sponsor the Global Generics & Biosimilars Awards each year, and this recognition of Samsung Bioepis was part of that. Informa is a publishing company and IQVIA is a data analytics consultant.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.